Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib plus endocrine therapy versus chemotherapy as first-line treatment for visceral metastatic breast cancer
2018-003648-22Phase 3Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ribociclib in breast cancer (2 arms), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Quality of life-adjusted early disease control. Started Jul 2019; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-003648-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003648-22.